Galecto Inc (GLTO)

$27.84 +4.24 (17.97%)
Market Cap 31.32M
Revenue (ttm) 0.00
Net Income (ttm) -21.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,998,800
Avg Vol 4,470,946
Day's Range N/A - N/A
Shares Out 1.33M
Stochastic %K 80%
Beta 1.45
Analysts Hold
Price Target $6.00

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 70 52 10
Website: galecto.com
Address:
Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark
P4jt
P4jt Nov. 14 at 3:16 PM
$GLTO Going to leave a lot of bag holders here……Only a matter of time….GOING DOWN….CHEERSP4
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 14 at 2:04 PM
$GLTO nice
0 · Reply
A_Aron1990
A_Aron1990 Nov. 14 at 2:01 PM
$GLTO im gonna make this my friday play i usually chase hype and get screwed but made a little off this one earlier this week and shes quiet i like it good lick and happy friday yall 🍻
0 · Reply
hannah_wilson33
hannah_wilson33 Nov. 14 at 12:30 PM
$GLTO setting up fo
0 · Reply
ReversalFox
ReversalFox Nov. 14 at 10:30 AM
$ARBB Clear to 9+ reminds me of how $GLTO started its run
1 · Reply
Nycbroker1
Nycbroker1 Nov. 14 at 9:34 AM
$RUBI RSI is 14. Totally oversold. $GLTO $NVVE
0 · Reply
SurfTheTicker
SurfTheTicker Nov. 14 at 8:54 AM
$TRUG $5 stock on paper $20+ like $GLTO accounting all attributes
1 · Reply
Nycbroker1
Nycbroker1 Nov. 14 at 8:13 AM
$RUBI $GLTO $NVVE
0 · Reply
PaulLaurent
PaulLaurent Nov. 14 at 6:48 AM
🌅 4:00am EST Watchlist $BCG – Q3 & 9M update: disciplined costs, flexible balance sheet, and pipeline visibility. Watch guidance color, margin mix, and year-end milestone pacing. $MLSS – Stable revenue with lower opex; operating leverage improving. Track adoption of computer-controlled injection systems, distribution expansion, and path to sustained profitability. $BTOC – Rev +16.5% to ~49.5 (company fig). Focus on network utilization, ops upgrades, and capacity/tech investments; watch mix and unit economics. $XPON – Expion360: Q3 highlights premium lithium battery traction across RV/marine/off-grid. Eyes on OEM wins, channel growth, backlog quality, inventory turns, and Nasdaq compliance. $GLTO – Potential multi-day runner. Favor VWAP holds, liquidity expansion, and clean pullback entries. Tone: Earnings color and execution updates lead. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.
0 · Reply
Bigwinner75
Bigwinner75 Nov. 14 at 6:39 AM
$GLTO if this stock has a solid support at 10 dollar. I would be concerned
1 · Reply
Latest News on GLTO
GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

Nov 10, 2025, 1:08 PM EST - 3 days ago

GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

MOVE

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Nov 10, 2025, 11:47 AM EST - 3 days ago

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Galecto Announces Acquisition of Damora Therapeutics

Nov 10, 2025, 7:00 AM EST - 4 days ago

Galecto Announces Acquisition of Damora Therapeutics

Galecto Reports Third Quarter 2025 Operating and Financial Results

Nov 6, 2025, 4:30 PM EST - 7 days ago

Galecto Reports Third Quarter 2025 Operating and Financial Results

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Oct 7, 2025, 1:05 PM EDT - 5 weeks ago

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Oct 7, 2025, 10:27 AM EDT - 5 weeks ago

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Galecto Reports Second Quarter 2025 Operating and Financial Results

Aug 5, 2025, 4:15 PM EDT - 3 months ago

Galecto Reports Second Quarter 2025 Operating and Financial Results

Galecto Reports First Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 6 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

Galecto Reports Full-Year 2024 Financial Results

Mar 19, 2025, 4:45 PM EDT - 8 months ago

Galecto Reports Full-Year 2024 Financial Results

Galecto to Participate in Upcoming Investor Conferences

Feb 6, 2025, 8:00 AM EST - 10 months ago

Galecto to Participate in Upcoming Investor Conferences

Galecto Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Galecto Reports Third Quarter 2024 Financial Results

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Oct 7, 2024, 8:45 AM EDT - 1 year ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Galecto Announces Reverse Stock Split

Aug 28, 2024, 9:00 AM EDT - 1 year ago

Galecto Announces Reverse Stock Split

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

May 1, 2024, 4:01 PM EDT - 1 year ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Dec 21, 2023, 4:05 PM EST - 2 years ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Galecto Announces Plans to Explore Strategic Alternatives

Sep 26, 2023, 4:01 PM EDT - 2 years ago

Galecto Announces Plans to Explore Strategic Alternatives

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Galecto to Present at Investor Conferences in September

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Galecto Reports Second Quarter Operating and Financial Results

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

Galecto Set to Join Russell Microcap® Index

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 23, 2023, 8:30 AM EDT - 2 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

Galecto to Present Poster at Upcoming ATS 2023 International Conference

May 17, 2023, 4:01 PM EDT - 2 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Galecto Reports First Quarter Operating and Financial Results

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Galecto Reports First Quarter Operating and Financial Results

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 18, 2023, 7:01 PM EDT - 2 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Galecto to Present Two Posters at AACR Annual Meeting 2023

Apr 13, 2023, 8:30 AM EDT - 2 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 9, 2023, 7:00 AM EST - 2 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Mar 2, 2023, 4:05 PM EST - 2 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Galecto to Participate in SVB Securities Global Biopharma Conference

Feb 1, 2023, 8:00 AM EST - 3 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Dec 7, 2022, 4:05 PM EST - 3 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 9:15 AM EST - 3 years ago

Galecto Reports Third Quarter Operating and Financial Results

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 8, 2022, 6:00 AM EST - 3 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Galecto to Participate in Jefferies London Healthcare Conference

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Galecto to Participate at Jefferies Healthcare Conference

May 31, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at Jefferies Healthcare Conference

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

May 26, 2022, 8:30 AM EDT - 3 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Mar 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Galecto Reports Financial Results for the Year Ended December 31, 2021

Feb 17, 2022, 5:00 PM EST - 4 years ago

Galecto Reports Financial Results for the Year Ended December 31, 2021

P4jt
P4jt Nov. 14 at 3:16 PM
$GLTO Going to leave a lot of bag holders here……Only a matter of time….GOING DOWN….CHEERSP4
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 14 at 2:04 PM
$GLTO nice
0 · Reply
A_Aron1990
A_Aron1990 Nov. 14 at 2:01 PM
$GLTO im gonna make this my friday play i usually chase hype and get screwed but made a little off this one earlier this week and shes quiet i like it good lick and happy friday yall 🍻
0 · Reply
hannah_wilson33
hannah_wilson33 Nov. 14 at 12:30 PM
$GLTO setting up fo
0 · Reply
ReversalFox
ReversalFox Nov. 14 at 10:30 AM
$ARBB Clear to 9+ reminds me of how $GLTO started its run
1 · Reply
Nycbroker1
Nycbroker1 Nov. 14 at 9:34 AM
$RUBI RSI is 14. Totally oversold. $GLTO $NVVE
0 · Reply
SurfTheTicker
SurfTheTicker Nov. 14 at 8:54 AM
$TRUG $5 stock on paper $20+ like $GLTO accounting all attributes
1 · Reply
Nycbroker1
Nycbroker1 Nov. 14 at 8:13 AM
$RUBI $GLTO $NVVE
0 · Reply
PaulLaurent
PaulLaurent Nov. 14 at 6:48 AM
🌅 4:00am EST Watchlist $BCG – Q3 & 9M update: disciplined costs, flexible balance sheet, and pipeline visibility. Watch guidance color, margin mix, and year-end milestone pacing. $MLSS – Stable revenue with lower opex; operating leverage improving. Track adoption of computer-controlled injection systems, distribution expansion, and path to sustained profitability. $BTOC – Rev +16.5% to ~49.5 (company fig). Focus on network utilization, ops upgrades, and capacity/tech investments; watch mix and unit economics. $XPON – Expion360: Q3 highlights premium lithium battery traction across RV/marine/off-grid. Eyes on OEM wins, channel growth, backlog quality, inventory turns, and Nasdaq compliance. $GLTO – Potential multi-day runner. Favor VWAP holds, liquidity expansion, and clean pullback entries. Tone: Earnings color and execution updates lead. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.
0 · Reply
Bigwinner75
Bigwinner75 Nov. 14 at 6:39 AM
$GLTO if this stock has a solid support at 10 dollar. I would be concerned
1 · Reply
Bigwinner75
Bigwinner75 Nov. 14 at 6:35 AM
$GLTO geez. I am scared. This is the new Tesla
0 · Reply
Bigwinner75
Bigwinner75 Nov. 14 at 6:32 AM
$GLTO today the big boys ( had 2 k ) followers not showing up. Maybe he did the rug pull for your followers
0 · Reply
SurfTheTicker
SurfTheTicker Nov. 14 at 4:33 AM
$TRUG $5 $NVVE .70 $GLTO $OPEN $CIFR BUY ZONES
0 · Reply
TheSwingLife
TheSwingLife Nov. 14 at 2:36 AM
$TRUG Monster move in the making! Everyone should have this on their watch list. $CLBT $ONDS $GLTO $QNRX
0 · Reply
ReversalFox
ReversalFox Nov. 14 at 12:50 AM
$ARBB Loading this here at $6.80 could be the next $GLTO $NVVE type runner micro float is squeezing now !
1 · Reply
mrmarc
mrmarc Nov. 14 at 12:37 AM
$GLTO - $35 eod Friday
1 · Reply
goalseeker
goalseeker Nov. 14 at 12:36 AM
$GLTO and then fryday 🔥!! for the shorts ,, bahahaha !!
0 · Reply
CM20
CM20 Nov. 14 at 12:26 AM
$GLTO I’ll be watching you when it all comes crashing back to earth.
0 · Reply
22Allin
22Allin Nov. 14 at 12:03 AM
$GLTO 3 days straight bear pussys being pounded hard
0 · Reply
Jozie12clicks
Jozie12clicks Nov. 14 at 12:01 AM
$GLTO where’s onetimer169 who was calling everyone an idiot? Glad I didn’t listen to him.
0 · Reply
SqueezrGames
SqueezrGames Nov. 13 at 10:52 PM
$DAL $NOW $GLTO $REKR watchlist
0 · Reply